1. Testicular choriocarcinoma: a rare variant that requires a unique treatment approach.
- Author
-
Reilley MJ and Pagliaro LC
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biomarkers, Tumor blood, Chorionic Gonadotropin blood, Humans, Male, Choriocarcinoma diagnosis, Choriocarcinoma secondary, Choriocarcinoma therapy, Testicular Neoplasms diagnosis, Testicular Neoplasms pathology, Testicular Neoplasms therapy
- Abstract
Testicular germ cell tumors represent the most common malignancy among young men. While 5-year overall survival and cure for this population is greater than 95%, choriocarcinoma is an aggressive subtype of this disease with far worse prognosis--5-year survival for choriocarcinoma is less than 80%. In order to be able to treat these patients appropriately, a provider must recognize characteristic features of choriocarcinoma including elevated human chorionic gonadotropin in a young man with testicular mass; the astute clinician should also know the signs and symptoms of choriocarcinoma syndrome, characterized by bleeding from metastatic sites, which represents a medical emergency and is associated with high morbidity and mortality. Treatment should be directed towards a goal of tumor marker normalization, and patients with refractory disease should be considered for advanced therapies and clinical trials. Choriocarcinoma is a unique and aggressive germ cell malignancy, and these patients require early aggressive treatment to improve their chance of survival.
- Published
- 2015
- Full Text
- View/download PDF